The instruments segment by product and services is estimated to lead the market growth during the forecast period.

According to a new market research study of “North America Anatomic Pathology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product and Service, Application, End User and Country.” The North America anatomic pathology market is expected to reach US$ 13,970.95 million by 2028 from US$ 8,870.41 million in 2021; it is estimated to grow at a CAGR of 6.7% from 2021 to 2028. The report highlights trends prevailing in the North America anatomic pathology market and the factors driving market along with those that act as hindrances.

Cancer has a major impact on society across the world. The burden of cancer on healthcare systems is significantly increasing worldwide as it is among the leading causes of death. According to the National Cancer Institute, in 2018, there were 18.1 million new cases and 9.5 million people died from the disease worldwide. ~30% of all premature deaths from noncommunicable diseases among adults aged 30–69 are caused because of cancer. Lung cancer is the most frequently diagnosed cancer in the world. The prevalence of diabetes is growing, especially in the world’s middle-income countries, due to increase in overweight, obesity, and unhealthy diet. Overweight and obesity are among the prime most risk factors causing Type 2 diabetes. According to the IDF Diabetes Atlas Ninth Edition, in 2019, ~463 million adults, from the age range 20–79 years, were living with diabetes; and this number would rise to 700 million. Owing to the increasing prevalence of cancer and other diseases, government agencies, healthcare providers, and institutions are being compelled to contribute toward disease diagnosis and treatment initiatives. Thus, a surge in the prevalence of cancer and other targeted diseases is driving the North America anatomic pathology market growth. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. The personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for specific actions. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even great potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is boosting the anatomic pathology market growth.

The COVID-19 pandemic and the redirection in healthcare resources have impacted every aspect of the diagnostics industry, including the anatomic pathology market. The closure of clinics, operation rooms, and physician offices, and the “stay-at-home” mandates across North America severely impacted the acquisition and submission of specimens for pathology evaluation. In the last two years, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals. Further, as most hospitals invested their efforts and resources in diagnosing and treating COVID-19, many planned surgeries were canceled or delayed. As a result, various early cancer detection systems were deactivated, and all autopsies were suspended. According to the World Economic Forum, 28 million elective surgeries and 38% of global cancer surgeries have been delayed. Thus, the number of surgical pathology and cytology samples received in anatomic pathology labs reduced significantly. As a result, the number of diagnostic tests has reduced. The reduction has further reduced the sales of anatomic pathology products during the Q2 of 2020. Moreover, due to the robust increase in COVID- 19 patients, pathology laboratories are now prioritizing and focusing on COVID-19 tests. The rapid increase in the number of infected patients in the US and Canada is likely to hamper the growth of the North America anatomy pathology market in the future. Currently, many countries are relaxing the lockdown restrictions, and most hospitals have resumed elective surgeries. As a result, the number of diagnostic tests is now increasing. However, due to the effects of the COVID-19 pandemic, the overall growth rate of the anatomic pathology market is less than the previous year.

Based on product and service, the North America anatomic pathology market is segmented into instruments, consumables, and services. By application, the North America anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment held the largest market share in 2021. The North America anatomic pathology market, based on end user, is segmented into hospitals, research laboratories, diagnostic laboratories, and others. Geographically, the North America anatomic pathology market can be segmented into U.S, Canada and Mexico.

F. HOFFMANN-LA ROCHE LTD., Danaher, Hologic, Inc., Agilent Technologies, Inc., BioGenex, Diapath S.p.A., Bio SB, MERCK KGaA, BD and PHC Holdings Corporation are among the leading companies operating in the North America anatomic pathology market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com